These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35872093)

  • 1. Classification of the Severity of COPD Exacerbations in Hospitalized Patients According to Rome vs GesEPOC Criteria.
    Amado Diago CA; Figueira Gonçalves JM; Golpe R; Esteban C; Garcia Talavera I; García-Martín S
    Arch Bronconeumol; 2023 Jan; 59(1):57-58. PubMed ID: 35872093
    [No Abstract]   [Full Text] [Related]  

  • 2. [Spanish COPD Guidelines (GesEPOC): Pharmacological treatment of stable COPD].
    Miravitlles M; Soler-Cataluña JJ; Calle M; Molina J; Almagro P; Quintano JA; Riesco JA; Trigueros JA; Piñera P; Simón A; López-Campos JL; Soriano JB; Ancochea J
    Aten Primaria; 2012 Jul; 44(7):425-37. PubMed ID: 22704760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordance in treatment of chronic obstructive pulmonary disease following GesEPOC guideline vs. GOLD.
    Figueira Gonçalves JM; Golpe R; Esteban C; Acosta-Sorensen M; Veiga I; Guzmán-Peralta I
    Rev Clin Esp (Barc); 2021 Nov; 221(9):536-539. PubMed ID: 34518150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery.
    Miravitlles M; Soler-Cataluña JJ; Calle M; Molina J; Almagro P; Quintano JA; Riesco JA; Trigueros JA; Piñera P; Simón A; López-Campos JL; Soriano JB; Ancochea J;
    Arch Bronconeumol; 2012 Jul; 48(7):247-57. PubMed ID: 22561012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial Treatment in Chronic Obstructive Pulmonary Disease According to GesEPOC 2021 vs. GesEPOC 2017. Approaching Criteria with GOLD 2021?
    Figueira Gonçalves JM; Golpe R; Esteban C; Amado Diago C; García Talavera I; Ramos Izquierdo C
    Arch Bronconeumol; 2022 Apr; 58(4):364-366. PubMed ID: 35312579
    [No Abstract]   [Full Text] [Related]  

  • 6. The Rationale for GesEPOC in Our Environment.
    Arnedillo Muñoz A
    Arch Bronconeumol; 2017 Jun; 53(6):293-294. PubMed ID: 28495074
    [No Abstract]   [Full Text] [Related]  

  • 7. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase.
    Miravitlles M; Soler-Cataluña JJ; Calle M; Molina J; Almagro P; Quintano JA; Trigueros JA; Cosío BG; Casanova C; Antonio Riesco J; Simonet P; Rigau D; Soriano JB; Ancochea J
    Arch Bronconeumol; 2017 Jun; 53(6):324-335. PubMed ID: 28477954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjusting the Level of Intervention in Patients with Chronic Obstructive Pulmonary Disease According to the Risk Stratification Proposed by the Spanish COPD Guidelines (GesEPOC) Version 2017.
    Erro Iribarren M; Alonso Pérez T; Soriano JB; Ancochea Bermúdez J
    Arch Bronconeumol (Engl Ed); 2020 Mar; 56(3):183-185. PubMed ID: 31722829
    [No Abstract]   [Full Text] [Related]  

  • 9. Order Set to Improve the Care of Patients Hospitalized for an Exacerbation of Chronic Obstructive Pulmonary Disease.
    Brown KE; Johnson KJ; DeRonne BM; Parenti CM; Rice KL
    Ann Am Thorac Soc; 2016 Jun; 13(6):811-5. PubMed ID: 27058777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication Regimens for Managing COPD Exacerbations.
    Putcha N; Wise RA
    Respir Care; 2018 Jun; 63(6):773-782. PubMed ID: 29794210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
    Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
    Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study.
    Dalon F; Roche N; Belhassen M; Nolin M; Pegliasco H; Deslée G; Housset B; Devillier P; Van Ganse E
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1839-1854. PubMed ID: 31692478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex Differences in Veterans Admitted to the Hospital for Chronic Obstructive Pulmonary Disease Exacerbation.
    Bade BC; DeRycke EC; Ramsey C; Skanderson M; Crothers K; Haskell S; Bean-Mayberry B; Brandt C; Bastian LA; Akgün KM
    Ann Am Thorac Soc; 2019 Jun; 16(6):707-714. PubMed ID: 30822098
    [No Abstract]   [Full Text] [Related]  

  • 14. β-Blocker use and incidence of chronic obstructive pulmonary disease exacerbations.
    Farland MZ; Peters CJ; Williams JD; Bielak KM; Heidel RE; Ray SM
    Ann Pharmacother; 2013 May; 47(5):651-6. PubMed ID: 23585645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GesEPOC 2021: One More Step Towards Personalized Treatment of COPD.
    Miravitlles M; Calle M; Soler-Cataluña JJ
    Arch Bronconeumol (Engl Ed); 2021 Jan; 57(1):9-10. PubMed ID: 32980163
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study.
    Papi A; Zheng J; Criner GJ; Fabbri LM; Calverley PMA
    Respir Med; 2019 Feb; 147():37-43. PubMed ID: 30704697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of inhaled bronchodilator therapy in patients hospitalized for non-life-threatening COPD exacerbations.
    Woods JA; Usery JB; Self TH; Finch CK
    South Med J; 2011 Nov; 104(11):742-5. PubMed ID: 22024782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acute exacerbations of chronic obstructive pulmonary disease].
    Chabot F; Gomez E; Guillaumot A; Kheir A; Chaouat A
    Presse Med; 2009 Mar; 38(3):485-95. PubMed ID: 19185446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.
    Chong J; Karner C; Poole P
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009157. PubMed ID: 22972134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which bronchodilator reversibility criteria can predict severe acute exacerbation in chronic obstructive pulmonary disease patients?
    Kim J; Kim WJ; Lee CH; Lee SH; Lee MG; Shin KC; Yoo KH; Lee JH; Lim SY; Na JO; Hwang HG; Hong Y; Lim MN; Yoo CG; Jung KS; Lee SD
    Respir Res; 2017 May; 18(1):107. PubMed ID: 28558829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.